Optimal Dosing Strategies and Managing AEs

Opinion
Video

Panelists discuss how they dose talquetamab in clinical practice, comparing its administration schedule to other bispecific antibodies and addressing dosing-related challenges they encounter.

Recent Videos
“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.
Barry Paul, MD, listed cilta-cel, anito-cel, and arlo-cel as 3 of the CAR T-cell therapies with the most promising efficacy in patients with multiple myeloma.
5 experts are featured in this series
4 experts in this video
4 experts in this video
4 experts in this video
5 experts are featured in this series
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
2 experts are featured in this series.
Related Content